INFLUENCE élevé Magazine Debuts Exclusive Dykema 2026 Special Issue Featuring Dentistry's Leading Voices

INFLUENCE élevé Magazine will debut the Dykema 2026 Special Issue at the 13th Annual Dykema DSO Conference, with publication on July 15 (digital and complimentary print while supplies last). The issue spotlights how dentistry’s business evolution and the responsible integration of artificial intelligence into patient care are shaping adoption priorities for dental organizations. Coverage includes leaders from organizations such as Pearl and Patient Prism, along with discussion of economic pressures and strategic technology uptake.

Analysis

Near-term, this is more a distribution-and-sentiment signal than a fundamental catalyst. The real beneficiaries are the incumbents already embedded in dental workflow and billing stacks — HSIC and, to a lesser extent, PDCO — because AI adoption in a fragmented DSO market usually gets bought through existing channels, not through greenfield software budgets. The second-order loser is standalone point-solution vendors: once AI is framed as a margin tool, buyers will pressure vendors to bundle features into broader practice-management or distribution contracts, which can cap pricing power and lengthen sales cycles.

The bigger economic lever is labor substitution, not incremental revenue. In dentistry, even a modest reduction in front-office and scheduling overhead can expand EBITDA for DSOs over 6-18 months, but only if implementation is fast and measurable; if adoption requires workflow redesign, the spend gets deferred. For HSIC, the upside is more about attach rate and software mix than a step-change in top-line, and there is no reason to pay up for the category unless recurring revenue conversion improves.

Contrarian view: the market may be overestimating how quickly AI becomes a paid, scaled seat in dentistry. Offices are still conservative buyers, so the next 1-3 months are likely narrative-only; the real test is whether upcoming earnings calls quantify churn, ARPU, or workflow penetration. Falsifier: if HSIC/PDCO do not show improved software attach or margin mix over the next two quarters, this remains marketing noise rather than a tradable adoption cycle.

Key Decisions for Investors

• No immediate position in HSIC on this item; wait for the next 1-2 earnings cycles to see whether dental software attach and recurring revenue mix actually improve. Treat flat margins or unchanged attach rates as a thesis break.
• Watch HSIC versus PDCO as a relative-value setup over 1-3 months; only consider a small long HSIC / short weaker healthcare distributor pair if management confirms AI-led cross-sell and higher recurring mix. Without that evidence, the trade is premature.
• Do not chase pure-play dental AI vendors via public proxies; the likely outcome is feature commoditization and bundle pressure, not a new standalone revenue pool. The better economics should accrue to incumbents with installed base and distribution.
• Set an alert for DSO commentary on labor savings and patient throughput into earnings season. If operators can show sub-12 month payback from AI/workflow tools, the whole dental software stack deserves a re-rate; if not, this stays a long-duration theme.